Search

Displaying results 3301 - 3310 of 5506 in total
  1. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.

  2. Drug

    SSR-126517E

    go.drugbank.com/drugs/DB05362
    Experimental

    SSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.

  3. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    It is being developed by Ascent Therapeutics.

  4. Drug

    Propacetamol

    go.drugbank.com/drugs/DB09288
    Investigational

    Propacetamol is a parenteral formulation of paracetamol and thus, it is a prodrug that is completely hydrolyzed to paracetamol. … [A32051] It is a derivative of [acetaminophen], or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester.

  5. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  6. Drug

    Desirudin

    go.drugbank.com/drugs/DB11095
    ApprovedWithdrawn

    It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. … It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis.

  7. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia. … However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of

  8. Drug

    Streptococcus pneumoniae type 3 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10321
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  9. Drug

    Streptococcus pneumoniae type 4 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10322
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  10. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10323
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.